• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

JMP Securities Sixth Annual Research Conference to Webcast Alexza's Corporate Presentation

Posted on: Thursday, 17 May 2007, 18:00 CDT

PALO ALTO, Calif., May 17 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. announced today that its corporate presentation will be webcast live during The Sixth Annual JMP Securities Research Conference on Tuesday, May 22, 2007 at 4:30 p.m. Eastern Time (1:30 p.m. local time). The presentation will be webcast from The Ritz-Carlton Hotel in San Francisco and may be accessed under the Investor Relations tab at http://www.alexza.com/ or at http://www.wsw.com/webcast/jmp4/ghdx/. The presentation will be archived for 14 days.

Alexza Pharmaceuticals is an emerging pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. The Company has five product candidates in clinical development; AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches, AZ-004 (Staccato loxapine) for the treatment of acute agitation in patients with schizophrenia, AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder, AZ-003 (Staccato fentanyl) for the treatment of patients with acute pain and AZ-007 (Staccato zaleplon) for the treatment of sleep disorder in patients who have difficulty falling asleep.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K/A for the year ended December 31, 2006, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Alexza Pharmaceuticals, Inc.

CONTACT: Thomas B. King, President & CEO of Alexza Pharmaceuticals,Inc., +1-650-687-3900, or tking@alexza.com

Web site: http://www.alexza.com/

Source: PRNewswire-FirstCall

More News in this Category